An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Melanoma
Both
Melanoma
Trial Information
An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations
Inclusion Criteria:
- Stage III or Stage IV melanoma
- No evidence of disease following resection of melanoma lesions
- Recovered from all prior surgical or adjuvant treatment-related toxicities
Exclusion Criteria:
- History of chronic inflammatory or autoimmune disease
- History of inflammatory bowel disease
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Pharmacokinetics: maximum plasma concentration of CP-675,206
Outcome Time Frame:
1 hour
Safety Issue:
No
Authority:
United States: Food and Drug Administration
Study ID:
A3671011
NCT ID:
NCT00431275
Start Date:
June 2006
Completion Date:
February 2008
Related Keywords:
- Melanoma
- Melanoma
Name | Location |
|---|---|
| Research Site | Mesa, Arizona |
| Research Site | Boulder, Colorado |
| Research Site | Boca Raton, Florida |
| Research Site | Albany, Georgia |
| Research Site | Albany, New York |
| Research Site | Allentown, Pennsylvania |
